Literature DB >> 14531000

Can pre-operative contrast-enhanced dynamic MR imaging for prostate cancer predict microvessel density in prostatectomy specimens?

Heinz-Peter Schlemmer1, Jonas Merkle, Rainer Grobholz, Tim Jaeger, Maurice Stephan Michel, Axel Werner, Jan Rabe, Gerhard van Kaick.   

Abstract

The aim of this study was to correlate quantitative dynamic contrast-enhanced MRI (DCE MRI) parameters with microvessel density (MVD) in prostate carcinoma. Twenty-eight patients with biopsy-proven prostate carcinoma were examined by endorectal MRI including multiplanar T2- and T1-weighted spin-echo and dynamic T1-weighted turbo-FLASH MRI during and after intravenous Gd-DTPA administration. Microvessels were stained on surgical specimens using a CD31 monoclonal antibody. The MVD was quantified in hot spots by counting (MVC) and determining the area fraction by morphometry (MVAF). The DCE MRI data were analyzed using an open pharmacokinetic two-compartment model. In corresponding anatomic locations the time shift (Deltat) between the beginning of signal enhancement of cancer and adjacent normal prostatic tissue, the degree of contrast enhancement and the contrast exchange rate constant (k21) were calculated. The MVC and MVAF were elevated in carcinoma (p<0.001 and p=0.002, respectively) and correlated to k21 (r=0.62, p<0.001 and r=0.80, p<0.001, respectively). k21-values of carcinoma were significantly higher compared with normal peripheral but not central zone tissue. Deltat was longer in high compared with low-grade tumors (p=0.025). The DCE MRI can provide important information about individual MVD in prostate cancer, which may be helpful for guiding biopsy and assessing individual prognosis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14531000     DOI: 10.1007/s00330-003-2025-2

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  38 in total

Review 1.  Prognostic factors in prostate cancer. College of American Pathologists Consensus Statement 1999.

Authors:  D G Bostwick; D J Grignon; M E Hammond; M B Amin; M Cohen; D Crawford; M Gospadarowicz; R S Kaplan; D S Miller; R Montironi; T F Pajak; A Pollack; J R Srigley; J W Yarbro
Journal:  Arch Pathol Lab Med       Date:  2000-07       Impact factor: 5.534

2.  Pharmacokinetic parameters in CNS Gd-DTPA enhanced MR imaging.

Authors:  G Brix; W Semmler; R Port; L R Schad; G Layer; W J Lorenz
Journal:  J Comput Assist Tomogr       Date:  1991 Jul-Aug       Impact factor: 1.826

3.  Dynamic TurboFLASH subtraction technique for contrast-enhanced MR imaging of the prostate: correlation with histopathologic results.

Authors:  G J Jager; E T Ruijter; C A van de Kaa; J J de la Rosette; G O Oosterhof; J R Thornbury; S H Ruijs; J O Barentsz
Journal:  Radiology       Date:  1997-06       Impact factor: 11.105

4.  Detection of extracapsular extension of prostate carcinoma with endorectal and phased-array coil MR imaging: multivariate feature analysis.

Authors:  K K Yu; H Hricak; R Alagappan; D M Chernoff; P Bacchetti; C J Zaloudek
Journal:  Radiology       Date:  1997-03       Impact factor: 11.105

5.  Multicompartment analysis of gadolinium chelate kinetics: blood-tissue exchange in mammary tumors as monitored by dynamic MR imaging.

Authors:  R E Port; M V Knopp; U Hoffmann; S Milker-Zabel; G Brix
Journal:  J Magn Reson Imaging       Date:  1999-09       Impact factor: 4.813

6.  Independent association of angiogenesis index with outcome in prostate cancer.

Authors:  R Mehta; A Kyshtoobayeva; T Kurosaki; E J Small; H Kim; R Stroup; C E McLaren; K T Li; J P Fruehauf
Journal:  Clin Cancer Res       Date:  2001-01       Impact factor: 12.531

7.  Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging.

Authors:  D F Gleason; G T Mellinger
Journal:  J Urol       Date:  1974-01       Impact factor: 7.450

8.  Cancer statistics, 1998.

Authors:  S H Landis; T Murray; S Bolden; P A Wingo
Journal:  CA Cancer J Clin       Date:  1998 Jan-Feb       Impact factor: 508.702

9.  Tumor angiogenesis correlates with progression after radical prostatectomy but not with pathologic stage in Gleason sum 5 to 7 adenocarcinoma of the prostate.

Authors:  M A Silberman; A W Partin; R W Veltri; J I Epstein
Journal:  Cancer       Date:  1997-02-15       Impact factor: 6.860

10.  Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma.

Authors:  N Weidner; P R Carroll; J Flax; W Blumenfeld; J Folkman
Journal:  Am J Pathol       Date:  1993-08       Impact factor: 4.307

View more
  48 in total

1.  Prediction of prostate cancer extracapsular extension with high spatial resolution dynamic contrast-enhanced 3-T MRI.

Authors:  B Nicolas Bloch; Elizabeth M Genega; Daniel N Costa; Ivan Pedrosa; Martin P Smith; Herbert Y Kressel; Long Ngo; Martin G Sanda; William C Dewolf; Neil M Rofsky
Journal:  Eur Radiol       Date:  2012-06-03       Impact factor: 5.315

Review 2.  Methods for volume assessment of prostate cancer.

Authors:  Heinz-Peter Schlemmer; Stefan Corvin
Journal:  Eur Radiol       Date:  2004-02-06       Impact factor: 5.315

3.  Cost-analysis of staging methods for lymph nodes in patients with prostate cancer: MRI with a lymph node-specific contrast agent compared to pelvic lymph node dissection or CT.

Authors:  Anke M Hövels; Roel A M Heesakkers; Eddy M Adang; Gerrit J Jager; Jelle O Barentsz
Journal:  Eur Radiol       Date:  2004-07-13       Impact factor: 5.315

4.  [Standardised scoring of a multi-parametric 3-T MRI for a targeted MRI-guided prostate biopsy].

Authors:  C Arsov; D Blondin; R Rabenalt; G Antoch; P Albers; M Quentin
Journal:  Urologe A       Date:  2012-06       Impact factor: 0.639

Review 5.  Diffusion-weighted (DW) and dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) for monitoring anticancer therapy.

Authors:  Anwar R Padhani; Aftab Alam Khan
Journal:  Target Oncol       Date:  2010-04-11       Impact factor: 4.493

Review 6.  Dynamic contrast-enhanced magnetic resonance imaging and pharmacokinetic models in prostate cancer.

Authors:  Tobias Franiel; Bernd Hamm; Hedvig Hricak
Journal:  Eur Radiol       Date:  2010-12-24       Impact factor: 5.315

7.  Reproducibility of image interpretation in MRI of the prostate: application of the sextant framework by two different radiologists.

Authors:  Ullrich Mueller-Lisse; Ulrike Mueller-Lisse; Juergen Scheidler; Gerhardt Klein; Maximilian Reiser
Journal:  Eur Radiol       Date:  2005-04-20       Impact factor: 5.315

Review 8.  Prostate MR imaging at high-field strength: evolution or revolution?

Authors:  Olivier Rouvière; Robert P Hartman; Denis Lyonnet
Journal:  Eur Radiol       Date:  2005-09-10       Impact factor: 5.315

Review 9.  [Whole body MRI--diagnostic strategy of the future?].

Authors:  M Goyen; H-P Schlemmer
Journal:  Radiologe       Date:  2007-10       Impact factor: 0.635

10.  The role of magnetic resonance imaging (MRI) in prostate cancer imaging and staging at 1.5 and 3 Tesla: the Beth Israel Deaconess Medical Center (BIDMC) approach.

Authors:  B Nicolas Bloch; Robert E Lenkinski; Neil M Rofsky
Journal:  Cancer Biomark       Date:  2008       Impact factor: 4.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.